Ab Science Paris (ABSCF) 17.9500 $ABSCF
AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
GlobeNewswire - Wed Jun 08, 10:54AM CDT
Following recommendation by the European Medicines Agency (EMA) to file masitinib for conditional marketing authorization in Amyotrophic Lateral Sclerosis (ALS), AB Science is holding an Investor & Analyst conference in New York on June 13, 2016
AB: 22.85 (+0.31)
AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization
GlobeNewswire - Mon Jun 06, 12:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announced today that Rapporteurs appointed by the European Medicines Agency (EMA) have recommended the filing of masitinib in combination with riluzole in the treatment of adult patients with amyotrophic lateral sclerosis (ALS) for conditional marketing authorization.
AB: 22.85 (+0.31)
AB Science Will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21st Congress of the European Hematology Association
GlobeNewswire - Mon May 30, 12:57AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that results from its phase 3 trial in severe systemic mastocytosis will be presented as an oral presentation at the 21 Congress of the European Hematology Association (June 9 - 12, 2016, Copenhagen, Denmark).
AB: 22.85 (+0.31)
AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
GlobeNewswire - Mon May 02, 12:53AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the filing for registration to European Medicines Agency (EMA) for masitinib in the treatment of adult patient with severe systemic mastocytosisunresponsive to optimal symptomatic treatment, with date of review process starting on 26 April 2016. Masitinib is the first treatment to be evaluated in this indication. Top-line results from this phase 3 were previously announced on 30 November 2015.
AB: 22.85 (+0.31)
AB Science will host live webcast on phase 3 interim analysis in ALS on 8 April 2016, from 5.30pm to 6.30pm CET
GlobeNewswire - Wed Apr 06, 12:02PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), is hosting a live webcast on the phase 3 interim analysis results of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) with key opinion leaders from this disease.
AB: 22.85 (+0.31)
AB Science : New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases
GlobeNewswire - Thu Mar 10, 11:16AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today reports the publication of four independent, peer-reviewed, expert opinion articles that highlight a growing recognition of masitinib as a candidate drug in the field of neurological and neurodegenerative disease.
AB: 22.85 (+0.31)
Systemic Mastocytosis Global Clinical Trials Review, H2, 2015 - Key Players are Novartis AG, AB Science SA & Blueprint Medicines - Research and Markets
BusinessWire - Mon Mar 07, 1:22PM CST
Research and Markets (http://www.researchandmarkets.com/research/hhbpkj/systemic) has announced the addition of the "Systemic Mastocytosis Global Clinical Trials Review, H2, 2015" report to their offering.
BPMC: 18.63 (-0.45)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 8.14 (-0.24), ADRO: 11.47 (-0.21), AVXL: 4.10 (-0.19), AMBX: (), ACH: 7.50 (-0.03), AMGN: 150.15 (-2.15), ADMP: 3.03 (-0.06), ABBV: 59.97 (-0.93)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.14 (-0.24), ADRO: 11.47 (-0.21), ARWR: 5.79 (-0.14), ADMP: 3.03 (-0.06), AMGN: 150.15 (-2.15), APTO: 2.70 (-0.10), AVXL: 4.10 (-0.19), AZN: 27.62 (-0.01), ABBV: 59.97 (-0.93), ARRY: 3.27 (+0.01)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 25.83 (+0.06), POZN: 5.94 (-0.43), CBMG: 15.27 (+0.03), OMER: 10.78 (-0.20)
Rheumatoid Arthritis Pipeline Review, H2 2015 - 200+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc73g7/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Rheumatoid ArthritisOverview - Therapeutics Development - Pipeline Products for Rheumatoid Arthritis - Overview - Pipeline Products for Rheumatoid Arthritis - Comparative Analysis - Rheumatoid Arthritis - Therapeutics under Development by Companies - Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes - Rheumatoid Arthritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Rheumatoid Arthritis - Products under Development by Companies - Rheumatoid Arthritis - Products under Investigation by Universities/Institutes - Rheumatoid Arthritis - Companies Involved in Therapeutics Development Companies Mentioned - 30 of the 200 Companies Featured - 3SBio Inc. - 4D Pharma Plc - 4SC AG - AB Science SA - AB2 Bio Ltd. - AbbVie Inc. - Ablynx NV - ACEA Biosciences, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegera Therapeutics Inc. - Alder Biopharmaceuticals Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Limited - Aprogen, Inc. - Arena Pharmaceuticals, Inc. - arGentis Pharmaceuticals, LLC - Arrien Pharmaceuticals, LLC - Arthrogen BV - Asahi Kasei Pharma Corp. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Avesthagen Limited - Avexxin AS - Axxam SpA - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited For more information visit http://www.researchandmarkets.com/research/mc73g7/rheumatoid
ALDR: 27.36 (-0.66), AZN: 27.62 (-0.01), AMGN: 150.15 (-2.15), ABBV: 59.97 (-0.93), ARNA: 1.87 (-0.02)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 39.31 (-1.77), AMGN: 150.15 (-2.15), AMPE: 3.35 (-0.15), LLY: 73.71 (-0.54), ENZ: 5.43 (-0.18), CCXI: 4.70 (-0.10), ABBV: 59.97 (-0.93), ARNA: 1.87 (-0.02), CELGZ: 1.33 (-0.07)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 18.63 (-0.45), BSPM: 5.90 (+0.43), ADRO: 11.47 (-0.21), ARWR: 5.79 (-0.14), ARQL: 1.78 (-0.01), AMGN: 150.15 (-2.15), CASI: 1.26 (unch), BMY: 70.57 (-1.16), CLBS: 0.52 (+0.02), AAAP: 28.59 (-0.41), CANF: 2.66 (-0.12), ABUS: 3.24 (-0.04), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), ABBV: 59.97 (-0.93), XLRN: 35.11 (-1.19), ARRY: 3.27 (+0.01)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.14 (-0.24), ARQL: 1.78 (-0.01), AMGN: 150.15 (-2.15), ATNM: 1.83 (+0.02), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), ABBV: 59.97 (-0.93), BXLT: 46.02 (-0.18), ARRY: 3.27 (+0.01)
Inflammatory Bowel Disease Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bgntqd/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Inflammatory Bowel Disease Overview - Therapeutics Development - Pipeline Products for Inflammatory Bowel Disease - Overview - Pipeline Products for Inflammatory Bowel Disease - Comparative Analysis - Inflammatory Bowel Disease - Therapeutics under Development by Companies - Inflammatory Bowel Disease - Therapeutics under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Inflammatory Bowel Disease - Products under Development by Companies - Inflammatory Bowel Disease - Products under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Companies Involved in Therapeutics Development Sample List of the 180 Companies - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Advinus Therapeutics Ltd. - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akari Therapeutics, Plc - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Alvine Pharmaceuticals, Inc. - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Amorepacific Corporation - Ampio Pharmaceuticals, Inc. - Amyra Biotech AG - Apogee Biotechnology Corporation - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - Atlantic Healthcare Plc - Avaxia Biologics, Inc. - Axxam SpA - Basilea Pharmaceutica AG - BioAtla, LLC - BIOCAD - BioLineRx, Ltd. - BioLingus AG - Bionovis SA - Biotec Pharmacon ASA - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/bg...flammatory
ARGS: 5.65 (-0.15), AMGN: 150.15 (-2.15), AMPE: 3.35 (-0.15), ABBV: 59.97 (-0.93), AKTX: 14.61 (-0.19), ARNA: 1.87 (-0.02)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.47 (unch), AMBX: (), CLDX: 4.39 (-0.02), ARQL: 1.78 (-0.01), CTIC: 0.39 (unch), CTMX: 9.55 (-0.50), ABBV: 59.97 (-0.93), XLRN: 35.11 (-1.19), ADXS: 8.14 (-0.24), AMGN: 150.15 (-2.15), BIND: 0.49 (+0.07), BMY: 70.57 (-1.16), BPTH: 1.90 (-0.17), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), CELGZ: 1.33 (-0.07)
Alzheimer's Disease - Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwvj4d/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Alzheimer's Disease Overview - Therapeutics Development - Pipeline Products for Alzheimer's Disease - Overview - Pipeline Products for Alzheimer's Disease - Comparative Analysis - Alzheimer's Disease - Therapeutics under Development by Companies - Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes - Alzheimer's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Alzheimer's Disease - Products under Development by Companies - Alzheimer's Disease - Products under Investigation by Universities/Institutes - Alzheimer's Disease - Companies Involved in Therapeutics Development(Partial List) - AB Science SA - AbbVie Inc. - AC Immune SA - Acelot, Inc. - Actinogen Limited - Acumen Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Aequus Pharmaceuticals Inc. - AFFiRiS AG - Alector LLC - Alkermes Plc - ALSP, Inc. - Alzhyme Pty Ltd - Alzinova AB - AlzProtect SAS - Amarantus Bioscience Holdings, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Aphios Corporation - Apodemus AB - Applied Research using OMIC Sciences, S.L. - Araclon Biotech, S.L. - Archer Pharmaceuticals, Inc. - ArmaGen,Inc. - Artery Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Ausio Pharmaceuticals, LLC - Avergen Ltd - Avineuro Pharmaceuticals, Inc. - Axerion Therapeutics, Inc. - Axon Neuroscience SE - Axovant Sciences Ltd. For more information visit http://www.researchandmarkets.com/research/xwvj4d/alzheimers
AXON: 11.91 (-0.52), AVXL: 4.10 (-0.19), AZN: 27.62 (-0.01), AMGN: 150.15 (-2.15), ABBV: 59.97 (-0.93), ALKS: 41.81 (-0.35)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.78 (-0.01), AMGN: 150.15 (-2.15), LLY: 73.71 (-0.54), BMY: 70.57 (-1.16), ATNM: 1.83 (+0.02), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), ABBV: 59.97 (-0.93), BXLT: 46.02 (-0.18), EXEL: 7.69 (+0.14), CELGZ: 1.33 (-0.07), ARRY: 3.27 (+0.01)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 8.14 (-0.24), ARWR: 5.79 (-0.14), AMBX: (), CLDX: 4.39 (-0.02), ADMP: 3.03 (-0.06), AMGN: 150.15 (-2.15), LLY: 73.71 (-0.54), BIND: 0.49 (+0.07), BMY: 70.57 (-1.16), AZN: 27.62 (-0.01), ABBV: 59.97 (-0.93), CORT: 5.40 (-0.04)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 25.83 (+0.06), ALKS: 41.81 (-0.35), ARGS: 5.65 (-0.15), ABBV: 59.97 (-0.93), ATHX: 2.16 (-0.03), ARNA: 1.87 (-0.02), ARRY: 3.27 (+0.01)
AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
GlobeNewswire - Wed Jun 08, 10:54AM CDT
Following recommendation by the European Medicines Agency (EMA) to file masitinib for conditional marketing authorization in Amyotrophic Lateral Sclerosis (ALS), AB Science is holding an Investor & Analyst conference in New York on June 13, 2016
AB: 22.85 (+0.31)
AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization
GlobeNewswire - Mon Jun 06, 12:52AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announced today that Rapporteurs appointed by the European Medicines Agency (EMA) have recommended the filing of masitinib in combination with riluzole in the treatment of adult patients with amyotrophic lateral sclerosis (ALS) for conditional marketing authorization.
AB: 22.85 (+0.31)
AB Science Will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21st Congress of the European Hematology Association
GlobeNewswire - Mon May 30, 12:57AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that results from its phase 3 trial in severe systemic mastocytosis will be presented as an oral presentation at the 21 Congress of the European Hematology Association (June 9 - 12, 2016, Copenhagen, Denmark).
AB: 22.85 (+0.31)
AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis
GlobeNewswire - Mon May 02, 12:53AM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announces the filing for registration to European Medicines Agency (EMA) for masitinib in the treatment of adult patient with severe systemic mastocytosisunresponsive to optimal symptomatic treatment, with date of review process starting on 26 April 2016. Masitinib is the first treatment to be evaluated in this indication. Top-line results from this phase 3 were previously announced on 30 November 2015.
AB: 22.85 (+0.31)
AB Science will host live webcast on phase 3 interim analysis in ALS on 8 April 2016, from 5.30pm to 6.30pm CET
GlobeNewswire - Wed Apr 06, 12:02PM CDT
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), is hosting a live webcast on the phase 3 interim analysis results of masitinib in the treatment of amyotrophic lateral sclerosis (ALS) with key opinion leaders from this disease.
AB: 22.85 (+0.31)
AB Science : New independent publications underscore the potential of masitinib in neurological and neurodegenerative diseases
GlobeNewswire - Thu Mar 10, 11:16AM CST
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today reports the publication of four independent, peer-reviewed, expert opinion articles that highlight a growing recognition of masitinib as a candidate drug in the field of neurological and neurodegenerative disease.
AB: 22.85 (+0.31)
Systemic Mastocytosis Global Clinical Trials Review, H2, 2015 - Key Players are Novartis AG, AB Science SA & Blueprint Medicines - Research and Markets
BusinessWire - Mon Mar 07, 1:22PM CST
Research and Markets (http://www.researchandmarkets.com/research/hhbpkj/systemic) has announced the addition of the "Systemic Mastocytosis Global Clinical Trials Review, H2, 2015" report to their offering.
BPMC: 18.63 (-0.45)
Pancreatic Cancer Pipeline Review, H2 2015
M2 - Tue Feb 09, 10:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/r58xq3/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatic Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatic CancerOverview - Therapeutics Development - Pipeline Products for Pancreatic Cancer - Overview - Pipeline Products for Pancreatic Cancer - Comparative Analysis - Pancreatic Cancer - Therapeutics under Development by Companies - Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes - Pancreatic Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatic Cancer - Products under Development by Companies - Pancreatic Cancer - Products under Investigation by Universities/Institutes - Pancreatic Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 3-V Biosciences, Inc. - 3B Pharmaceuticals GmbH - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - ACF Pharmaceuticals, LLC - Adamed Sp. z o.o. - Adamis Pharmaceuticals Corporation - Aduro BioTech, Inc. - Advantagene, Inc. - Advaxis, Inc. - Agenus, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alchemia Limited - Alethia Biotherapeutics Inc. - Allinky Biopharma - Almac Discovery Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Andarix Pharmaceuticals, Inc. - ANP Technologies, Inc. - APEIRON Biologics AG - Apexigen, Inc. - Aphios Corporation - APIM Therapeutics AS - Apogenix GmbH - Aposense Ltd. - Arch Biopartners, Inc. - Argon Pharma S.L. For more information visit http://www.researchandmarkets.com/research/r5...tic_cancer
ADXS: 8.14 (-0.24), ADRO: 11.47 (-0.21), AVXL: 4.10 (-0.19), AMBX: (), ACH: 7.50 (-0.03), AMGN: 150.15 (-2.15), ADMP: 3.03 (-0.06), ABBV: 59.97 (-0.93)
Global Melanoma Pipeline Review 2015
M2 - Tue Feb 09, 10:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/xdhrqg/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanomaand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - MelanomaOverview - Therapeutics Development - Pipeline Products for Melanoma - Overview - Pipeline Products for Melanoma - Comparative Analysis - Melanoma - Therapeutics under Development by Companies - Melanoma - Therapeutics under Investigation by Universities/Institutes - Melanoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Melanoma - Products under Development by Companies - Melanoma - Products under Investigation by Universities/Institutes - Melanoma - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - AB Science SA - AbbVie Inc. - ACF Pharmaceuticals, LLC - Adamis Pharmaceuticals Corporation - Adaptimmune Limited - Aduro BioTech, Inc. - Advaxis, Inc. - Aeterna Zentaris Inc. - Affichem SA - Agalimmune Ltd - Agenus, Inc. - Agilvax, Inc. - AGV Discovery, SAS - AIMM Therapeutics B.V. - Alethia Biotherapeutics Inc. - Altor BioScience Corporation - Amgen Inc. - Anavex Life Sciences Corp. - Antigen Express, Inc. - APEIRON Biologics AG - Aphios Corporation - APO-T B.V. - Aposense Ltd. - Applied Immune Technologies Ltd - Aptose Biosciences Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Axelar AB - Azaya Therapeutics, Inc. - Basilea Pharmaceutica AG For more information visit http://www.researchandmarkets.com/research/xdhrqg/melanoma
ADXS: 8.14 (-0.24), ADRO: 11.47 (-0.21), ARWR: 5.79 (-0.14), ADMP: 3.03 (-0.06), AMGN: 150.15 (-2.15), APTO: 2.70 (-0.10), AVXL: 4.10 (-0.19), AZN: 27.62 (-0.01), ABBV: 59.97 (-0.93), ARRY: 3.27 (+0.01)
Stroke - Pipeline Review 2015
M2 - Tue Feb 09, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/23dsxv/stroke_pipeline) has announced the addition of the "Stroke - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Stroke Overview - Therapeutics Development - Pipeline Products for Stroke - Overview - Pipeline Products for Stroke - Comparative Analysis - Stroke - Therapeutics under Development by Companies - Stroke - Therapeutics under Investigation by Universities/Institutes - Stroke - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Stroke - Products under Development by Companies - Stroke - Products under Investigation by Universities/Institutes - Stroke - Companies Involved in Therapeutics Development Companies Mentioned Include: - AB Science SA - Acorda Therapeutics, Inc. - Acticor Biotech - Biogen, Inc. - BioTime, Inc. - Cardax Pharmaceuticals, Inc. - Cellular Biomedicine Group, Inc. - CHA Bio & Diostech Co., Ltd. - CoDa Therapeutics, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - NoNO, Inc. - Omeros Corporation - Panacea Pharmaceuticals, Inc. - PharmatrophiX, Inc. - Pharmicell Co., Ltd. - Phoenix Biotechnology, Inc. - Phylogica Limited - PhytoHealth Corporation - Pozen, Inc. - Primary Peptides, Inc. - (Others) For more information visit http://www.researchandmarkets.com/research/23...e_pipeline
ACOR: 25.83 (+0.06), POZN: 5.94 (-0.43), CBMG: 15.27 (+0.03), OMER: 10.78 (-0.20)
Rheumatoid Arthritis Pipeline Review, H2 2015 - 200+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mc73g7/rheumatoid) has announced the addition of the "Rheumatoid Arthritis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritisand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Rheumatoid ArthritisOverview - Therapeutics Development - Pipeline Products for Rheumatoid Arthritis - Overview - Pipeline Products for Rheumatoid Arthritis - Comparative Analysis - Rheumatoid Arthritis - Therapeutics under Development by Companies - Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes - Rheumatoid Arthritis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Rheumatoid Arthritis - Products under Development by Companies - Rheumatoid Arthritis - Products under Investigation by Universities/Institutes - Rheumatoid Arthritis - Companies Involved in Therapeutics Development Companies Mentioned - 30 of the 200 Companies Featured - 3SBio Inc. - 4D Pharma Plc - 4SC AG - AB Science SA - AB2 Bio Ltd. - AbbVie Inc. - Ablynx NV - ACEA Biosciences, Inc. - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegera Therapeutics Inc. - Alder Biopharmaceuticals Inc. - AlphaMab Co., Ltd - Amgen Inc. - Amura Holdings Limited - Aprogen, Inc. - Arena Pharmaceuticals, Inc. - arGentis Pharmaceuticals, LLC - Arrien Pharmaceuticals, LLC - Arthrogen BV - Asahi Kasei Pharma Corp. - Aslan Pharmaceuticals Pte. Ltd. - Astellas Pharma Inc. - AstraZeneca Plc - Avesthagen Limited - Avexxin AS - Axxam SpA - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited For more information visit http://www.researchandmarkets.com/research/mc73g7/rheumatoid
ALDR: 27.36 (-0.66), AZN: 27.62 (-0.01), AMGN: 150.15 (-2.15), ABBV: 59.97 (-0.93), ARNA: 1.87 (-0.02)
Crohn's Disease (Regional Enteritis) - Pipeline Review Report H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/crzbr7/crohns_disease) has announced the addition of the "Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Crohn's Disease (Regional Enteritis)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Crohn's Disease (Regional Enteritis)Overview - Therapeutics Development - Pipeline Products for Crohn's Disease (Regional Enteritis)- Overview - Pipeline Products for Crohn's Disease (Regional Enteritis)- Comparative Analysis - Crohn's Disease (Regional Enteritis)- Therapeutics under Development by Companies - Crohn's Disease (Regional Enteritis)- Therapeutics under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Crohn's Disease (Regional Enteritis)- Products under Development by Companies - Crohn's Disease (Regional Enteritis)- Products under Investigation by Universities/Institutes - Crohn's Disease (Regional Enteritis)- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Alba Therapeutics Corporation - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Avaxia Biologics, Inc. - BioAtla, LLC - BIOCAD - BioLingus AG - Bionovis SA - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Calypso Biotech SA - Celgene Corporation - Celltrion, Inc. - ChemoCentryx, Inc. - ChironWells GmbH - Chong Kun Dang Pharmaceutical Corp. - CLL Pharma - Commence Bio, Inc. - Daiichi Sankyo Company, Limited - DBV Technologies S.A. - Eisai Co., Ltd. - Eli Lilly and Company - Emergent BioSolutions Inc. - Enterome Bioscience SA - Enzo Biochem, Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/cr...ns_disease
EBS: 39.31 (-1.77), AMGN: 150.15 (-2.15), AMPE: 3.35 (-0.15), LLY: 73.71 (-0.54), ENZ: 5.43 (-0.18), CCXI: 4.70 (-0.10), ABBV: 59.97 (-0.93), ARNA: 1.87 (-0.02), CELGZ: 1.33 (-0.07)
Global Liver Cancer Pipeline Review, H2 2015 - 150+ Companies & Drug Profiles
M2 - Tue Feb 09, 8:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/5j6swm/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Liver CancerOverview - Therapeutics Development - Pipeline Products for Liver Cancer- Overview - Pipeline Products for Liver Cancer- Comparative Analysis - Liver Cancer- Therapeutics under Development by Companies - Liver Cancer- Therapeutics under Investigation by Universities/Institutes - Liver Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Liver Cancer- Products under Development by Companies - Liver Cancer- Products under Investigation by Universities/Institutes - Liver Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - ACROVIS Pharma AG - Adaptimmune Limited - Aduro BioTech, Inc. - Advanced Accelerator Applications SA - Advenchen Laboratories, LLC - Alfact Innovation - Alnylam Pharmaceuticals, Inc. - American Gene Technologies International Inc. - Amgen Inc. - AndroScience Corporation - APAvadis Biotechnologies Srl - Arbutus Biopharma Corporation - ArQule, Inc. - Array BioPharma Inc. - Arrowhead Research Corporation - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bayer AG - Bio-Cancer Treatment International Limited - BioCancell Ltd - Biogazelle - Bioneer Corporation - BioStar Pharmaceuticals, Inc. - Blueprint Medicines - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - CASI Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/5j...ver_cancer
BPMC: 18.63 (-0.45), BSPM: 5.90 (+0.43), ADRO: 11.47 (-0.21), ARWR: 5.79 (-0.14), ARQL: 1.78 (-0.01), AMGN: 150.15 (-2.15), CASI: 1.26 (unch), BMY: 70.57 (-1.16), CLBS: 0.52 (+0.02), AAAP: 28.59 (-0.41), CANF: 2.66 (-0.12), ABUS: 3.24 (-0.04), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), ABBV: 59.97 (-0.93), XLRN: 35.11 (-1.19), ARRY: 3.27 (+0.01)
Colorectal Cancer Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/44bmjz/colorectal_cancer) has announced the addition of the "Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Colorectal Cancerand special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Colorectal CancerOverview - Therapeutics Development - Pipeline Products for Colorectal Cancer- Overview - Pipeline Products for Colorectal Cancer- Comparative Analysis - Colorectal Cancer- Therapeutics under Development by Companies - Colorectal Cancer- Therapeutics under Investigation by Universities/Institutes - Colorectal Cancer- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Colorectal Cancer- Products under Development by Companies - Colorectal Cancer- Products under Investigation by Universities/Institutes - Colorectal Cancer- Companies Involved in Therapeutics Development Companies Mentioned - Sample List of the 200 Companies Featured - 2cureX ApS - 3-V Biosciences, Inc. - 4SC AG - AB Science SA - AbbVie Inc. - AbGenomics International, Inc. - Actinium Pharmaceuticals, Inc. - Adamed Sp. z o.o. - Advaxis, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Allinky Biopharma - Amgen Inc. - Antibe Therapeutics, Inc. - Apexigen, Inc. - Aphios Corporation - Aposense Ltd. - Arisaph Pharmaceuticals, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - BeiGene(Beijing) Co.,Ltd - BioAtla, LLC - Biocon Limited - Bionomics Limited - Bionovis SA - Biotecnol, Inc. For more information visit http://www.researchandmarkets.com/research/44...tal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ADXS: 8.14 (-0.24), ARQL: 1.78 (-0.01), AMGN: 150.15 (-2.15), ATNM: 1.83 (+0.02), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), ABBV: 59.97 (-0.93), BXLT: 46.02 (-0.18), ARRY: 3.27 (+0.01)
Inflammatory Bowel Disease Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bgntqd/inflammatory) has announced the addition of the "Inflammatory Bowel Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Inflammatory Bowel Disease Overview - Therapeutics Development - Pipeline Products for Inflammatory Bowel Disease - Overview - Pipeline Products for Inflammatory Bowel Disease - Comparative Analysis - Inflammatory Bowel Disease - Therapeutics under Development by Companies - Inflammatory Bowel Disease - Therapeutics under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Inflammatory Bowel Disease - Products under Development by Companies - Inflammatory Bowel Disease - Products under Investigation by Universities/Institutes - Inflammatory Bowel Disease - Companies Involved in Therapeutics Development Sample List of the 180 Companies - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Advinus Therapeutics Ltd. - Aerpio Therapeutics, Inc. - Ajinomoto Pharmaceuticals Co., Ltd. - Akari Therapeutics, Plc - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - Allozyne, Inc. - Altheus Therapeutics, Inc. - Alvine Pharmaceuticals, Inc. - Am-Pharma B.V. - Amakem NV - Amgen Inc. - Amorepacific Corporation - Ampio Pharmaceuticals, Inc. - Amyra Biotech AG - Apogee Biotechnology Corporation - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - Atlantic Healthcare Plc - Avaxia Biologics, Inc. - Axxam SpA - Basilea Pharmaceutica AG - BioAtla, LLC - BIOCAD - BioLineRx, Ltd. - BioLingus AG - Bionovis SA - Biotec Pharmacon ASA - BioTherapeutics Inc. For more information visit http://www.researchandmarkets.com/research/bg...flammatory
ARGS: 5.65 (-0.15), AMGN: 150.15 (-2.15), AMPE: 3.35 (-0.15), ABBV: 59.97 (-0.93), AKTX: 14.61 (-0.19), ARNA: 1.87 (-0.02)
Head And Neck Cancer Therapeutics Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/bls9lh/head_and_neck) has announced the addition of the "Head And Neck Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Head And Neck Cancer Overview - Therapeutics Development - Pipeline Products for Head And Neck Cancer - Overview - Pipeline Products for Head And Neck Cancer - Comparative Analysis - Head And Neck Cancer - Therapeutics under Development by Companies - Head And Neck Cancer - Therapeutics under Investigation by Universities/Institutes - Head And Neck Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Head And Neck Cancer - Products under Development by Companies - Head And Neck Cancer - Products under Investigation by Universities/Institutes - Head And Neck Cancer - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acceleron Pharma, Inc. - Advaxis, Inc. - Alchemia Limited - Altor BioScience Corporation - Ambrx, Inc. - Amgen Inc. - ANP Technologies, Inc. - arGEN-X BV - ArQule, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - AVEO Pharmaceuticals, Inc. - Bayer AG - Bexion Pharmaceuticals, LLC. - BIND Therapeutics, Inc. - Bio-Path Holdings, Inc. - BioDiem Ltd - Bionovis SA - Biotest AG - Boehringer Ingelheim GmbH - Boston Biomedical, Inc. - Bristol-Myers Squibb Company - CEL-SCI Corporation - Celgene Corporation - Cell Medica Limited - Cellceutix Corporation - Celldex Therapeutics, Inc. - Celltrion, Inc. - Centrose LLC - Cristal Therapeutics - Critical Outcome Technologies Inc. - CTI BioPharma Corp. - CytomX Therapeutics, Inc. - Daiichi Sankyo Company, Limited - EcoBiotics Limited For more information visit http://www.researchandmarkets.com/research/bl...d_and_neck
CVM: 0.47 (unch), AMBX: (), CLDX: 4.39 (-0.02), ARQL: 1.78 (-0.01), CTIC: 0.39 (unch), CTMX: 9.55 (-0.50), ABBV: 59.97 (-0.93), XLRN: 35.11 (-1.19), ADXS: 8.14 (-0.24), AMGN: 150.15 (-2.15), BIND: 0.49 (+0.07), BMY: 70.57 (-1.16), BPTH: 1.90 (-0.17), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), CELGZ: 1.33 (-0.07)
Alzheimer's Disease - Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/xwvj4d/alzheimers) has announced the addition of the "Alzheimer's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Alzheimer's Disease Overview - Therapeutics Development - Pipeline Products for Alzheimer's Disease - Overview - Pipeline Products for Alzheimer's Disease - Comparative Analysis - Alzheimer's Disease - Therapeutics under Development by Companies - Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes - Alzheimer's Disease - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Alzheimer's Disease - Products under Development by Companies - Alzheimer's Disease - Products under Investigation by Universities/Institutes - Alzheimer's Disease - Companies Involved in Therapeutics Development(Partial List) - AB Science SA - AbbVie Inc. - AC Immune SA - Acelot, Inc. - Actinogen Limited - Acumen Pharmaceuticals, Inc. - Addex Therapeutics Ltd - Aequus Pharmaceuticals Inc. - AFFiRiS AG - Alector LLC - Alkermes Plc - ALSP, Inc. - Alzhyme Pty Ltd - Alzinova AB - AlzProtect SAS - Amarantus Bioscience Holdings, Inc. - Amgen Inc. - Anavex Life Sciences Corp. - Aphios Corporation - Apodemus AB - Applied Research using OMIC Sciences, S.L. - Araclon Biotech, S.L. - Archer Pharmaceuticals, Inc. - ArmaGen,Inc. - Artery Therapeutics, Inc. - AskAt Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Asubio Pharma Co., Ltd. - Ausio Pharmaceuticals, LLC - Avergen Ltd - Avineuro Pharmaceuticals, Inc. - Axerion Therapeutics, Inc. - Axon Neuroscience SE - Axovant Sciences Ltd. For more information visit http://www.researchandmarkets.com/research/xwvj4d/alzheimers
AXON: 11.91 (-0.52), AVXL: 4.10 (-0.19), AZN: 27.62 (-0.01), AMGN: 150.15 (-2.15), ABBV: 59.97 (-0.93), ALKS: 41.81 (-0.35)
Metastatic Colorectal Cancer Pipeline Review, H2 2015
M2 - Mon Feb 08, 11:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/pdf2gt/metastatic) has announced the addition of the "Metastatic Colorectal Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Colorectal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Metastatic Colorectal Cancer Overview - Therapeutics Development - Pipeline Products for Metastatic Colorectal Cancer - Overview - Pipeline Products for Metastatic Colorectal Cancer - Comparative Analysis - Metastatic Colorectal Cancer - Therapeutics under Development by Companies - Metastatic Colorectal Cancer - Therapeutics under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Metastatic Colorectal Cancer - Products under Development by Companies - Metastatic Colorectal Cancer - Products under Investigation by Universities/Institutes - Metastatic Colorectal Cancer - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - AB Science SA - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advenchen Laboratories, LLC - Alchemia Limited - Amgen Inc. - Apexigen, Inc. - ArQule, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - Bavarian Nordic A/S - Baxalta Incorporated - Bayer AG - Biocon Limited - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Celon Pharma Sp. z o.o. - Cornerstone Pharmaceuticals, Inc. - DanDrit Biotech A/S - Dr. Reddy's Laboratories Limited - EirGenix Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EnGeneIC Ltd - Epirus Biopharmaceuticals, Inc. - Etubics Corporation - Exelixis, Inc. For more information visit http://www.researchandmarkets.com/research/pdf2gt/metastatic
ARQL: 1.78 (-0.01), AMGN: 150.15 (-2.15), LLY: 73.71 (-0.54), BMY: 70.57 (-1.16), ATNM: 1.83 (+0.02), AZN: 27.62 (-0.01), AVEO: 0.99 (+0.05), ABBV: 59.97 (-0.93), BXLT: 46.02 (-0.18), EXEL: 7.69 (+0.14), CELGZ: 1.33 (-0.07), ARRY: 3.27 (+0.01)
Global Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rv4d7j/hormone) has announced the addition of the "Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview - Therapeutics Development - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview - Pipeline Products for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes - Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development Companies Featured - Partial List - A. Menarini Industrie Farmaceutiche Riunite Srl - AB Science SA - AbbVie Inc. - Adamis Pharmaceuticals Corporation - Advaxis, Inc. - Aeterna Zentaris Inc. - Alethia Biotherapeutics Inc. - Ambrx, Inc. - Amgen Inc. - AnGes MG, Inc. - Angion Biomedica Corp. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrowhead Research Corporation - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - ATLAB Pharma SAS - Bavarian Nordic A/S - Bayer AG - Beta Pharma, Inc. - BIND Therapeutics, Inc. - Bio-Cancer Treatment International Limited - Biscayne Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - CellCentric Ltd - Celldex Therapeutics, Inc. - Corcept Therapeutics Incorporated - CureVac GmbH - CytoVac A/S - DexTech Medical AB - Eisai Co., Ltd. - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/rv4d7j/hormone
ADXS: 8.14 (-0.24), ARWR: 5.79 (-0.14), AMBX: (), CLDX: 4.39 (-0.02), ADMP: 3.03 (-0.06), AMGN: 150.15 (-2.15), LLY: 73.71 (-0.54), BIND: 0.49 (+0.07), BMY: 70.57 (-1.16), AZN: 27.62 (-0.01), ABBV: 59.97 (-0.93), CORT: 5.40 (-0.04)
Multiple Sclerosis - Pipeline Review, H2 2015 Featuring 174 Companies
M2 - Fri Feb 05, 9:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/97qgw2/multiple) has announced the addition of the "Multiple Sclerosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Sclerosis Overview - Therapeutics Development - Pipeline Products for Multiple Sclerosis - Overview - Pipeline Products for Multiple Sclerosis - Comparative Analysis - Multiple Sclerosis - Therapeutics under Development by Companies - Multiple Sclerosis - Therapeutics under Investigation by Universities/Institutes - Multiple Sclerosis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Sclerosis - Products under Development by Companies - Multiple Sclerosis - Products under Investigation by Universities/Institutes - Multiple Sclerosis - Companies Involved in Therapeutics Development - 4D Pharma Plc - 4SC AG - AB Science SA - AbbVie Inc. - Ablynx NV - Acorda Therapeutics, Inc. - Actelion Ltd - Addex Therapeutics Ltd - Aegera Therapeutics Inc. - Aegis Therapeutics, LLC - Affectis Pharmaceuticals AG - AiCuris GmbH & Co. KG - Alkermes Plc - Allozyne, Inc. - Amarna Therapeutics B.V. - Antipodean Pharmaceuticals, Inc. - Antisense Therapeutics Limited - Antitope Limited - Aphios Corporation - Apitope International NV - Arena Pharmaceuticals, Inc. - Argos Therapeutics, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artielle ImmunoTherapeutics, Inc. - Athersys, Inc. - Axxam SpA - Baliopharm AG - Bio-Cancer Treatment International Limited - BIOCAD - Biocon Limited - Biogen, Inc. - Biogenomics Limited - Biokine Therapeutics Ltd. - Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/97qgw2/multiple About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ACOR: 25.83 (+0.06), ALKS: 41.81 (-0.35), ARGS: 5.65 (-0.15), ABBV: 59.97 (-0.93), ATHX: 2.16 (-0.03), ARNA: 1.87 (-0.02), ARRY: 3.27 (+0.01)
